Gang Wu's team at Washington University found the catalyst maintains high performance with minimal precious metal use.

Tomb Raider: Catalyst is indeed delayed to 2028, as many had suspected. Confirmation comes from Amazon’s video game boss, Jeffrey Gattis, who told The Game Business that Catalyst is now due out in ...

ROME, July 16 (Reuters) - Angelini Pharma said on Thursday it had completed the acquisition of U.S. rare-disease drug maker Catalyst Pharmaceuticals (CPRX.O), opens new tab in a $4.1 billion ‌deal ...

Seasoned investors will already know this, but those newer to investing may not be aware of the lockup periods that come with IPOs. When a company goes public, early investors and employees who've ...

Marc Santos is a Guides Staff Writer from the Philippines with a BA in Communication Arts and over six years of experience in writing gaming news and guides. He plays just about everything, from ...

We independently review everything we recommend. We may make money from the links on our site. Learn more› By Elissa Sanci Elissa Sanci is a senior writer who has reported on label makers, tumblers, ...

The Case-Mate IP68 Waterproof Large Phone Pouch is a highly-rated accessory for summer water activities. It features IP68 waterproof protection, a touch-friendly screen, and built-in buoyancy to ...

All products featured here are independently selected by our editors and writers. If you buy something through links on our site, Mashable may earn an affiliate commission. Years of testing went into ...

With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalyst Pharmaceuticals and its potential blockbuster, Firdapse, for $4.1 billion. Rome-based ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. The Italian company Angelini Pharma ...

Rare-disease specialist Catalyst Pharmaceuticals is set to be acquired by healthcare group Angelini Pharma in a $4.1 billion deal. Angelini will pay $31.50 for each of Nasdaq-listed Catalyst’s ...

The “catalyst theory” of California law governing attorney’s fees sometimes allows a plaintiff to obtain fees even in the absence of a favorable judgment, if the plaintiff can show that the lawsuit ...